Forte Biosciences, Inc. (FBRX) Balance Sheet

The balance sheet has exhibited extreme volatility, with total assets swinging from $17.9M in 2024Q3 to over $200M in 2026Q2, a pattern inconsistent with operational growth and indicative of periodic, large-scale equity financing. This trajectory signals a business model entirely dependent on external capital markets to fund its clinical pipeline, rather than generating internal value. The recent surge in equity to $183.8M appears to be a strategic move to extend cash runway ahead of critical clinical milestones for the FB-102 program.

The headline liquidity metrics appear robust, but the trend reveals a rapid depletion of cash reserves from the 2025Q4 peak. This burn is consistent with the escalating R&D expenses noted in the income statement analysis and suggests the company is actively spending down its capital to advance clinical trials. The current ratio's improvement is driven by the recent capital raise, not by operational cash generation, meaning the buffer against shocks is finite and directly tied to the next financing event.

The equity section is dominated by a massive and growing accumulated deficit, which has increased by over $140M in the last ten quarters. This reflects the cumulative cash burn from the failed FB-401 program and the ongoing investment in FB-102, with no offsetting retained earnings. The quality of equity is therefore low, as it is composed almost entirely of investor capital that has been consumed by R&D, making the company highly reliant on future dilutive financing to sustain operations.